O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
Eric Morand, C. Arriens, L. Geraldino-Pardilla, Ann E Clarke, S. Pomponi, C. Hobar, Thomas L. Wegman, Ravi Koti, Subhashis Banerjee, R. V. Vollenhoven
{"title":"O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus","authors":"Eric Morand, C. Arriens, L. Geraldino-Pardilla, Ann E Clarke, S. Pomponi, C. Hobar, Thomas L. Wegman, Ravi Koti, Subhashis Banerjee, R. V. Vollenhoven","doi":"10.1136/lupus-2024-el.41","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517941,"journal":{"name":"Oral Presentations","volume":"9 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Presentations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2024-el.41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
